This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: July 12, 2026·Last reviewed: August 4, 2026·Methodology v4.1

Researched By

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: August 4, 2026 · This page is informational and does not constitute medical advice.

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

GLP-1 maintenance: staying on and stepping down

Quick answer

For most patients, weight regain is common after stopping GLP-1 therapy, so many clinicians treat obesity as a chronic condition requiring maintenance dosing. Some patients use lower maintenance doses; this should be clinician-directed.

Why weight often returns

GLP-1 medications work while they are taken. Trials and real-world data show substantial regain after discontinuation for many patients, which is why maintenance is a serious consideration.

Lower maintenance doses

Some patients maintain on reduced doses. Evidence for specific maintenance schedules is still developing; see our microdosing overview for the marketing-versus-evidence distinction.

Frequently asked questions

Do I have to take GLP-1 medication forever?

Many patients regain weight after stopping, so clinicians often frame it as long-term therapy. Whether and how to step down is an individual clinical decision.

Sources

U.S. Food and Drug Administration — labels and safety communications.
Peer-reviewed clinical trials cited above.
Our methodology and medical review policy.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.